06 May SAFEGUARD
The SAFEGUARD study will evaluate the safety and efficacy of an investigational medicine called SAB-142 in delaying disease progression in people newly diagnosed with T1D.
For more information visit: https://clinicaltrials.gov/study/NCT07187531
Participant Eligibility
Eligibility includes:
-12 to 40 years old
-T1D diagnosis within the past three months
Contact
The Outreach Team
(800) 888-4187
Additional Study Details
Full Study Title
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
Study ID: IRB06096
ClinicalTrials.gov Link: NCT07187531
Start Date: 11/25/2025
End Date: 12/31/2028
Investigator(s)
Dr. Kurt Griffin kgriffin@benaroyaresearch.org
Dr. Sandra Lord SLord@benaroyaresearch.org
Please contact the outreach team with questions
Accepts Healthy Volunteers?
No
Study Site(s)
Benaroya Research Institute
1201 Ninth Ave.
Seattle, Washington 98101
